THE UNIVERSITY OF TOKYO   Global NanoBio Network Japanese
Ministry of Education, Culture, Sports, Science and Technology “Research and Development in a New Converting Field Based on Nanotechnology and Materials Science”
Center for NanoBio Integration
The University of Tokyo Center for NanoBio Integration
Center ConceptResearch ScopLaboratoriesBoard MembersPrincipal InvestigatorsイベントUniversity Corporate Relations News Paper / MediaAwardsNewslettersLinkContact usInternal Communication
HOME >> Principal Investigators >> Principal Investigators

Principal Investigators

Combination therapy of TGF-beta inhibitor and anticancer nanocarriers

We have recently found that an application of TGF-beta type I receptor (TbetaR-I) inhibitor at a low dose together with anticancer nanocarriers (e.g. micelle-adriamycin) dramatically reduce the growth of several experimental intractable solid tumors, including pancreatic adenocarcinoma and diffuse-type gastric cancer (Kano et al. PNAS 2007). TbetaR-I inhibitor decreased pericyte coverage of the endothelium specifically in tumor neovasculature and promoted accumulation of nanocarriers in the tumors. In this project, we will study the accumulation of various nanocarriers into tumors in the presence of TbetaR-I inhibitor. We also study the effects of the micelle-adriamycin and TbetaR-I inhibitor combination therapy on cancers other than pancreatic adenocarcinoma and diffuse-type gastric cancer.

Affiliation Department of Molecular Pathology,
Graduate School of Medicine,
The University of Tokyo
Major Field Molecular Pathology
Co-investigator Mitsunobu R. KANO
Makoto Kurachi
TEL +81-3-5841-3345
FAX +81-3-5841-3354
Address 7-3-1 Hougo, Bunkyo-ku, Tokyo 113-0033
Co-worker Kazunori KATAOKA


Copyright(C)2005 The University of Tokyo. All Rights Reserved.